Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for primary immunodeficiency disease.

R M Blaese1, K W Culver

  • 1Cellular Immunology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Immunodeficiency Reviews
|January 1, 1992
PubMed
Summary

Gene therapy shows promise for inherited and acquired diseases. Primary immunodeficiency diseases are prime candidates for current gene therapy strategies, particularly severe combined immunodeficiency (SCID).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The treatment of adenosine deaminase deficiency.

Immunology today·2014
Same author

A novel approach using transcomplementing adenoviral vectors for gene therapy of adrenocortical cancer.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2002
Same author

Biosynthetic ganciclovir triphosphate: its isolation and characterization from ganciclovir-treated herpes simplex thymidine kinase-transduced murine cells.

Biochemical and biophysical research communications·2001
Same author

AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits.

Gene therapy·2001
Same author

Development of a skin-based metabolic sink for phenylalanine by overexpression of phenylalanine hydroxylase and GTP cyclohydrolase in primary human keratinocytes.

Gene therapy·2001
Same author

Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.

Blood·2000

Area of Science:

  • Biotechnology
  • Medical Genetics
  • Immunology

Background:

  • Gene therapy presents a novel therapeutic avenue for monogenic, polygenic, and acquired disorders.
  • Significant challenges remain in gene therapy development, including gene identification, efficient delivery systems, and regulated gene expression.

Purpose of the Study:

  • To explore the potential of gene therapy for treating genetic disorders, with a focus on primary immunodeficiency diseases.
  • To discuss the feasibility of current gene therapy technologies for inherited diseases.

Main Methods:

  • Reviewing the current state of gene therapy technology and its application to genetic disorders.
  • Analyzing the suitability of primary immunodeficiency diseases for gene therapy interventions.
  • Examining strategies for gene correction in totipotent bone marrow stem cells and mature cells.

Main Results:

  • Primary immunodeficiency diseases are particularly amenable to gene therapy using existing technologies.
  • Gene therapy for ADA-deficient SCID is feasible, with preliminary results demonstrating potential.
  • Correction of mature cells may require periodic re-administration of gene transfer.

Conclusions:

  • Gene therapy holds significant potential for treating a range of genetic disorders.
  • Primary immunodeficiency diseases represent a promising area for the clinical application of gene therapy.
  • Further development in gene delivery and regulation is crucial for broader gene therapy success.

Related Experiment Videos